Novoheart Limited is a global stem cell biotechnology company dedicated to human heart engineering with corporate offices and laboratories in the United States, Canada, and Hong Kong. Novoheart's scientific team has pioneered a range of bioengineering technologies collectively known as the MyHeart platform, including first human mini-heart “novoHeart” that is capable of pumping and ejecting fluid.
It is currently partnering with a pharmaceutical company to develop human heart tissues and chambers that carry a hereditary neurodegenerative disease. It is anticipated that the pharmaceutical company will be able to use the developed pathological tissues as a unique drug discovery and drug screening platform for effective therapies targeting the heart-associated issues of these specific diseases. Novoheart has corporate offices and laboratories in the United States and Canada, and it is headquartered in Hong Kong. It is also currently completing the build out a large commercial laboratory in Asia to enable it to service additional potential commercial partnerships, which are under discussion.
